Autoantibody against survivin in patients with systemic sclerosis

Journal of Rheumatology

Volumn 37, Issue 9, 2010, Pages 1864-1870

  Koike, Yuta ^a   Muroi, Eiji ^a   Yoshizaki, Ayumi ^a   Ogawa, Fumihide ^a   Yanaba, Koichi ^b   Takenaka, Motoi ^a   Shimizu, Kazuhiro ^a   Sato, Shinichi ^c  

^a NAGASAKI UNIVERSITY   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

Autoantibody; Survivin; Systemic sclerosis

Indexed keywords

AUTOANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; RECOMBINANT PROTEIN; SURVIVIN;

ADULT; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOBLOTTING; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; AUTOANTIBODIES; CYSTEINE PROTEINASE INHIBITORS; FEMALE; HUMANS; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; SCLERODERMA, SYSTEMIC;

EID: 77956462090     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.091087     Document Type: Article

References (32)

1. Okano Y. Antinuclear antibody in systemic sclerosis (scleroderma). Rheum Dis Clin North Am 1996;22:709-35.
2. Iwata Y, Ogawa F, Komura K, Muroi E, Hara T, Shimizu K, et al. Autoantibody against peroxiredoxin I, an antioxidant enzyme, in patients with systemic sclerosis: possible association with oxidative stress. Rheumatology 2007;46:790-5.
3. Nishijima C, Hayakawa I, Matsushita T, Komura K, Hasegawa M, Takehara K, et al. Autoantibody against matrix metalloproteinase-3 in patients with systemic sclerosis. Clin Exp Immunol 2004;138:357-63.
4. Sato S, Hayakawa I, Hasegawa M, Fujimoto M, Takehara K. Function blocking autoantibodies against matrix metalloproteinase-1 in patients with systemic sclerosis. J Invest Dermatol 2003;120:542-7.
5. Matucci Cerinic M, Kahaleh MB. Beauty and the beast. The nitric oxide paradox in systemic sclerosis. Rheumatology 2002;41:843-7.
6. Sgonc R, Gruschwitz MS, Boeck G, Sepp N, Gruber J, Wick G. Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95. Arthritis Rheum 2000;43:2550-62.
7. Kim R, Tanabe K, Uchida Y, Emi M, Inoue H, Toge T. Current status of the molecular mechanisms of anticancer drug-induced apoptosis. The contribution of molecular-level analysis to cancer chemotherapy. Cancer Chemother Pharmacol 2002;50:343-52.
8. Hussein MR, Haemel AK, Wood GS. Apoptosis and melanoma: molecular mechanisms. J Pathol 2003;199:275-88.
9. Li F, Ling X. Survivin study: an update of "what is the next wave"? J Cell Physiol 2006;208:476-86.
10. Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 2003;22:8581-9.
11. Banks DP, Plescia J, Altieri DC, Chen J, Rosenberg SH, Zhang H, et al. Survivin does not inhibit caspase-3 activity. Blood 2000;96:4002-3.
12. Li C, Wu Z, Liu M, Pazgier M, Lu W. Chemically synthesized human survivin does not inhibit caspase-3. Protein Sci 2008;17:1624-9.
13. Fortugno P, Wall NR, Giodini A, O'Connor DS, Plescia J, Padgett KM, et al. Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function. J Cell Sci 2002;115:575-85.
14. Li F, Altieri DC. Transcriptional analysis of human survivin gene expression. Biochem J 1999;344 Pt 2:305-11.
15. Uren AG, Wong L, Pakusch M, Fowler KJ, Burrows FJ, Vaux DL, et al. Survivin and the inner centromere protein INCENP show similar cell-cycle localization and gene knockout phenotype. Curr Biol 2000;10:1319-28.
16. Bokarewa M, Lindblad S, Bokarew D, Tarkowski A. Balance between survivin, a key member of the apoptosis inhibitor family, and its specific antibodies determines erosivity in rheumatoid arthritis. Arthritis Res Ther 2005;7:R349-58.
17. Okazaki S, Ogawa F, Iwata Y, Hara T, Muroi E, Komura K, et al. Autoantibody against caspase-3, an executioner of apoptosis, in patients with systemic sclerosis. Rheumatol Int 2010;30:871-8.
18. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23:581-90.
19. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
20. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
21. Clements PJ, Lachenbruch PA, Seibold JR, Zee B, Steen VD, Brennan P, et al. Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol 1993;20:1892-6.
22. Sato S, Ihn H, Kikuchi K, Takehara K. Antihistone antibodies in systemic sclerosis. Association with pulmonary fibrosis. Arthritis Rheum 1994;37:391-4.
23. Sato S, Hasegawa M, Fujimoto M, Tedder TF, Takehara K. Quantitative genetic variation in CD19 expression correlates with autoimmunity. J Immunol 2000;165:6635-43.
24. Sato S, Ihn H, Soma Y, Igarashi A, Tamaki T, Kikuchi K, et al. Antihistone antibodies in patients with localized scleroderma. Arthritis Rheum 1993;36:1137-41.
25. Ogawa F, Shimizu K, Muroi E, Hara T, Hasegawa M, Takehara K, et al. Serum levels of 8-isoprostane, a marker of oxidative stress, are elevated in patients with systemic sclerosis. Rheumatology 2006;45:815-8.
26. Sgonc R, Gruschwitz MS, Dietrich H, Recheis H, Gershwin ME, Wick G. Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J Clin Invest 1996;98:785-92.
27. Casiano CA, Martin SJ, Green DR, Tan EM. Selective cleavage of nuclear autoantigens during CD95 (Fas/APO-1)-mediated T cell apoptosis. J Exp Med 1996;184:765-70.
28. Panchenko MV, Farber HW, Korn JH. Induction of heme oxygenase-1 by hypoxia and free radicals in human dermal fibroblasts. Am J Physiol Cell Physiol 2000;278:C92-C101.
29. Suematsu M, Wakabayashi Y, Ishimura Y. Gaseous monoxides: a new class of microvascular regulator in the liver. Cardiovasc Res 1996;32:679-86.
30. Butler AR, Flitney FW, Williams DL. NO, nitrosonium ions, nitroxide ions, nitrosothiols and iron-nitrosyls in biology: a chemist's perspective. Trends Pharmacol Sci 1995;16:18-22.
31. Rohayem J, Diestelkoetter P, Weigle B, Oehmichen A, Schmitz M, Mehlhorn J, et al. Antibody response to the tumor-associated inhibitor of apoptosis protein survivin in cancer patients. Cancer Res 2000;60:1815-7.
32. Megliorino R, Shi FD, Peng XX, Wang X, Chan EK, Tan EM, et al. Autoimmune response to anti-apoptotic protein survivin and its association with antibodies to p53 and c-myc in cancer detection. Cancer Detect Prev 2005;29:241-8.